- Molecular NameCarmustine
- SynonymBCNU; Bischlorethylnitrosourea; Bischlorethylnitrosurea; Carmustin
- Weight214.052
- Drugbank_IDDB00262
- ACS_NO154-93-8
- Show 2D model
- LogP (experiment)1.256
- LogP (predicted, AB/LogP v2.0)1.45
- pkaN/A
- LogD (pH=7, predicted)1.45
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.6
- LogSw (predicted, AB/LogsW2.0)10.87
- Sw (mg/ml) (predicted, ACD/Labs)5.4
- No.of HBond Donors1
- No.of HBond Acceptors5
- No.of Rotatable Bonds5
- TPSA61.77
- StatusFDA approved
- AdministrationIntravenous, wafer for implant
- PharmacologyA mustard gas-related α-chloro-nitrosourea compound used as an alkylating agent in chemotherapy.
- Absorption_value100.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability11.5
- Protein binding77.0
- Volume of distribution (VD)3.25 L/kg; 5.1 L/kg (patients with advanced neoplasms)
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic (CYP1A2-mediated)
- Half life0.36 h
- ExcretionExcreted primarily in the urine; about 10% is excreted as carbon dioxide via the lungs. Very small amounts (1%) are detected in the faeces.
- Urinary ExcretionN/A
- Clerance56 ml/min/kg; 77.6 ml/min/kg (patients with advanced neoplasms).
- ToxicityHypotension was the most prominent feature with high dose carmustine administration.
- LD50 (rat)20 mg/kg
- LD50 (mouse)45 mg/kg